Starting LDL cholesterol–lowering therapy is associated with substantial reductions in cardiovascular disease.

A Journal of the American Medical Association (JAMA) analysis by Navar et al. [1] reinforces a critical truth for cardiovascular prevention: cumulative LDL cholesterol exposure drives lifetime Atherosclerosis Cardiovascular Disease (ASCVD) risk. Even modest LDL-C elevations in early adulthood can accelerate plaque formation over decades — and earlier intervention meaningfully reduces long-term cardiovascular events.

Core finding: Starting LDL cholesterol–lowering therapy earlier in adulthood — even at modest LDL-C elevations — is associated with substantial reductions in lifetime ASCVD risk. The study used long-term modeling across multiple cohorts and showed that delaying treatment allows cumulative LDL-C exposure (“cholesterol burden”) to accelerate atherosclerosis.

Key insights: • Cumulative LDL C exposure matters more than short-term LDL C levels. Earlier intervention reduces plaque formation over decades.

• Individuals with borderline LDL-C (100–129 mg/dL) may still benefit from earlier treatment, especially with additional risk factors.

• Risk calculators underestimate lifetime risk because they focus on 10-year horizons.

• Precision in LDL-C measurement is essential — small inaccuracies can shift patients across treatment thresholds.

• Population-level impact: Earlier LDL-C management could meaningfully reduce ASCVD events across the lifespan.

Clinical implication: Accurate LDL-C testing and correct risk stratification are foundational to identifying who benefits from early therapy — and who may be undertreated under current paradigms.

Preventing and controlling elevated LDL-C could avert CVD deaths and extend healthy life expectancy globally. Despite advances in LDL-C management, the absolute burden has continued to rise since 1990 due to population growth and aging.

[1] Association of Early Cholesterol Treatment with Lifetime Risk of Atherosclerotic Cardiovascular Disease. Authors: Navar et al., JAMA, 2024.